Destined to fail, page-8

Will be interesting to see subset analysis of overall PFS in those patients who had liver only disease ( as opposed to PFS in the liver). If there is significant prolongation of survival once liver disease is controlled, one would be fairly confident of prolonged Overall Survival.

Most oncologists like to hear that a treatment is shown to have OS benefit before they use it. PFS is a surrogate marker often used in chemotherapy trials, but many oncologists are not satisfied unless there is an Overall Survival benefit.

Methinks if one looks at patients with liver only disease, if the spheres slow progression there should be an OS benefit. In these patients it is the liver which is the critical organ and they die from liver failure unless the liver progression can be halted.